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Introduction
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and
the third leading cause of cancer-related mortality worldwide.1,2 Early detection of
HCC is important as it has been shown to improve overall survival, particularly when
patients are able to receive potentially curative therapy such as resection or orthotopic
liver transplantation.3 The diagnosis of HCC may be made noninvasively by imaging
findings alone, often without the need for percutaneous biopsy, in patients who are
considered to be at high risk for HCC.4–6 Consequently, radiologists must be accurate
in their interpretation and reporting of liver imaging so that therapy may be rendered to
patients with HCC in an appropriate and timely manner. The Liver Imaging Reporting
and Data System (LI-RADS®) was conceived to address this need. Free-text reports
often contain vague wording and may vary based on the radiologist practice setting
and experience level. This, in turn, may lead to confusion among clinical teams responsible for the management of patients at risk for or with HCC. LI-RADS provides a
standardized lexicon, strict diagnostic criteria, an easy-to-follow diagnostic algorithm,
and reporting guidelines to improve the consistency and clarity of radiologist interpretation and reporting.
One benefit of LI-RADS is improved communication between radiologists and
clinicians. According to the LI-RADS diagnostic algorithm, each liver observation in a
patient at high risk for HCC is assigned a category (from LR-1 to LR-5) reflecting the
relative likelihood of being HCC.7 Interrater agreement for LI-RADS categorization is
substantial, and structured LI-RADS reporting has been shown to improve reporting
49
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Abstract: The Liver Imaging Reporting and Data System (LI-RADS®) is a comprehensive
system for standardizing the terminology, technique, interpretation, reporting, and data collection
of liver observations in individuals at high risk for hepatocellular carcinoma (HCC). LI-RADS
is supported and endorsed by the American College of Radiology (ACR). Upon its initial release
in 2011, LI-RADS applied only to liver observations identified at CT or MRI. It has since been
refined and expanded over multiple updates to now also address ultrasound-based surveillance,
contrast-enhanced ultrasound for HCC diagnosis, and CT/MRI for assessing treatment response
after locoregional therapy. The LI-RADS 2018 version was integrated into the HCC diagnosis,
staging, and management practice guidance of the American Association for the Study of Liver
Diseases (AASLD). This article reviews the major LI-RADS updates since its 2011 inception
and provides an overview of the currently published LI-RADS algorithms.
Keywords: LI-RADS, v2018, CT, MRI, CEUS, US, HCC, liver imaging, reporting, cirrhosis
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consistency.8,9 These studies were largely conducted among
expert radiologists at high-volume centers, and further data
among community radiologists are needed. LI-RADS is supported and endorsed by the American College of Radiology
(ACR) and in 2018 was integrated into the American Association for the Study of Liver Diseases (AASLD) guidance
statement for HCC.1
In this article, we review the expansions and updates of
LI-RADS since its 2011 inception, including the LI-RADS
ultrasound surveillance algorithm, the LI-RADS CT/MRI

diagnostic algorithm (Figure 1), the LI-RADS contrastenhanced ultrasound (CEUS) diagnostic algorithm, and the
LI-RADS CT/MRI treatment response algorithm. Major
changes to the LI-RADS v2018 CT/MRI diagnostic algorithm are highlighted, and a glimpse into future directions
of LI-RADS is provided.

Overview of major LI-RADS updates
LI-RADS is a dynamic system, with updates released regularly to incorporate user feedback, expanding knowledge, and

CT/MRI LI-RADS® v2018 CORE
Untreated observation without pathologic proof in patient at high risk for HCC
If cannot be categorized due to image degradation or omission

LR-NC

If definite TIV

LR-TIV

If definitely benign

LR-1

If probably benign

LR-2

If probably or definitely malignant but not HCC specific (eg, if targetoid)

LR-M

Otherwise, use CT/MRI diagnostic table below
If intermediate probability of malignancy

LR-3

If probably HCC

LR-4

If definitely HCC

LR-5

CT/MRI diagnostic table
APHE

No APHE

Observation size (mm)

Nonrim APHE

<20

≥20

<10

10–19

≥20

LR-3

LR-4

Count additional major features:

None

LR-3

LR-3

LR-3

• Enhancing “capsule”
• Nonperipheral “washout”
• Threshold growth

One

LR-3

LR-4

LR-4

≥Two

LR-4

LR-4

LR-4

LR-4

LR-5

LR-4

LR-5

LR-5

LR-5
LR-6

Observations in this cell are categorized based on one additional major feature:
• LR-4 – if enhancing “capsule”
• LR-5 – if nonperipheral “washout” OR threshold growth

If unsure about the presence of any major feature: characterize that feature as absent
Figure 1 LI-RADS CT/MRI diagnostic algorithm and table v2018.
Notes: Reproduced with permission from American College of Radiology. Liver Imaging Reporting and Data System version 2018 core. Available from: https://www.acr.
org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS.16
Abbreviations: ACR, American College of Radiology; APHE, Arterial phase hyperenhancement; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data
System; LR-NC, LR-noncategorizable; TIV, tumor in vein.
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technological advances.10 The major changes to LI-RADS
for each update are enumerated in the following sections.
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LI-RADS v2011
The initial version of LI-RADS was released in 2011 with
a standardized lexicon and five major categories for classifying observations in the liver: LR-1 (definitely benign),
LR-2 (probably benign), LR-3 (intermediate probability for
HCC), LR-4 (probably HCC), and LR-5 (definitely HCC).11

LI-RADS v2013
The first major update to LI-RADS was released in 2013. It
introduced a diagnostic table and imaging atlas. Modifications to the LR-5 category were made to achieve congruency
between the Organ Procurement and Transplantation Network (OPTN) Class 5 and LR-5. Three new categories were
formed: LR5 treated was congruent with the OPTN Class 5T
category, OM (other malignancy) to account for malignant
entities other than HCC that may occur in the liver, and LR5V
for definitely HCC with the presence of tumor in vein (TIV).

LI-RADS v2014
The 2014 LI-RADS update introduced material on hepatobiliary agents. The diagnostic algorithm was modified
and some of the terminology was simplified. In particular,
the designations A (≤19 mm) and B (≥20 mm), which split
LR-4 and LR-5 categories based on observation size, were
removed.12 A split cell was introduced into the algorithm for
10–19 mm observations with arterial phase hyperenhancement (APHE) and one additional major feature for HCC;
observations in this cell with “washout” and visibility on
antecedent screening ultrasound were assigned LR-5us as
per the 2011 AASLD guidelines,13 observations in this cell
meeting criteria for threshold growth were assigned LR-5g
for congruency with OPTN Class 5A-g,14 and all other observations in this cell were assigned LR-4. OM was changed
to LR-M (probably or definitely malignant, but not specific

for HCC), in recognition that corresponding lesions were
not always an “other malignancy” but could be HCC and
sometimes even could be benign. The lexicon and atlas were
refined and expanded.

LI-RADS v2017
LI-RADS v2017 added new algorithms for US surveillance,
CEUS diagnosis, and CT/MRI treatment response assessment. The category LR-noncategorizable (LR-NC) was
added to describe observations that cannot be categorized
due to image degradation or omission. LR-5V was renamed
LR-TIV in recognition that a minority of TIV observations
represent non-HCC malignancy.15 Additionally, the threshold
growth definition was modified, and new explicit criteria for
LR-M were introduced.

LI-RADS v2018
The 2018 update achieved a major milestone by unifying
LI-RADS and AASLD. The process of unification required
revision of the LR-5 category (Table 1). In particular, the
requirement for visibility at antecedent US for LR-5 designation for 10–19 mm observations with nonrim APHE
and “washout” was removed. The LR-5 nomenclature was
simplified by removal of the -us and -g qualifiers. Additionally, the LI-RADS definition of threshold growth was also
simplified to match that of the United Network for Organ
Sharing and the Organ Procurement and Transplantation
Network (UNOS-OPTN).16

US LI-RADS
Overview

Ultrasound is the most commonly used method for surveillance in patients at risk for HCC. It has the benefit of being
a noninvasive, accessible, safe, and low-cost screening tool
for HCC. In a meta-analysis of 15 scientific studies on HCC
surveillance in patients with cirrhosis, sonography had a
pooled sensitivity of 47% for early-stage cancer detection.17

Table 1 Major changes to CT/MRI LI-RADS v2018
Major changes to CT/MRI LI-RADS v2018*
Type of change

Description

Substantive

Requirement of visibility on antecedent US for LR-5 designation of 10–19 mm observations with nonrim APHE and
“washout” removed
OPTN definition of threshold growth adopted: ≥50% size increase of a mass in ≤6 months
-us removed as LR-5 qualifier
-g removed as LR-5 qualifier

Substantive
Nomenclatural
Nomenclatural

Note: *No changes made to CEUS LI-RADS or ultrasound LI-RADS.
Abbreviations: APHE, arterial phase hyperenhancement; CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System; OPTN, Organ
Procurement and Transplantation Network.
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Two prospective, randomized controlled trials in East Asia
have shown that ultrasound surveillance decreased HCCrelated mortality by 31%–37%.18,19 However, until now, there
has been a lack of standardization of ultrasound interpretation
and reporting. An ACR-endorsed working group developed a
new LI-RADS algorithm specific to the interpretation of HCC
screening and surveillance by ultrasound (US LI-RADS).20
Standardization of ultrasound technique and radiology reporting in high-risk individuals should improve communication
between physicians and unify surveillance algorithms at different institutions, as accomplished by the CR/MRI LI-RADS
diagnostic algorithm.20 The appropriate patient population
for the application of US LI-RADS is listed in Table 2. The
primary at-risk population includes patients with cirrhosis
from any etiology. The benefit of surveillance is unknown
in adults with nonalcoholic steatohepatitis or hepatitis C
infection in the absence of cirrhosis; however, these patients
may be included in surveillance populations depending on
regional practice guidelines. Patients with decompensated
Child–Pugh C cirrhosis are excluded due to limited life
expectancy unless the patient is a liver transplant candidate;

Table 2 The inclusion and exclusion criteria of LI-RADS (CT,
MRI, CEUS, and ultrasound surveillance)
Surveillance ultrasound target population
• Inclusion:
 Adults with cirrhosis of any cause
 Subsets of adult patients with chronic HBV infection, even in
the absence of cirrhosis
 Asian male hepatitis B carriers over age 40 years
 Asian female hepatitis B carriers over age 50 years
 Hepatitis B carrier with family history of HCC
 African or North American blacks with hepatitis B
• Exclusion:
 Child–Pugh C cirrhosis, unless patient is a transplant candidate
• Population in which benefit of surveillance is uncertain:
 Adults with NASH but without cirrhosis
 Adults with chronic hepatitis C without cirrhosis
Diagnostic population for LI-RADS (CT, MRI, and CEUS)
• Inclusion:
 Adults with cirrhosis
 Chronic hepatitis B
 Current or prior HCC including adult liver transplantation
candidates and patients posttransplant
• Exclusion:
 Cirrhosis due to vascular disorder or congenital hepatic
fibrosis
 Pediatric patients
Notes: Target populations for screening and surveillance and target population
for diagnostic imaging with CT, MRI, or CEUS. Guidelines based on the American
Association for Study of Liver Diseases (AASLD).1
Abbreviations: CEUS, contrast-enhanced ultrasound; HCC, hepatocellular
carcinoma; HPV, hepatitis B virus; LI-RADS, Liver Imaging Reporting and Data
System; NASH, nonalcoholic steatohepatitis.
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however, the best strategy for HCC surveillance in transplant
candidates is currently unclear.
The US LI-RADS algorithm includes two components: 1)
an ultrasound category (Figure 2) and 2) visualization score
(Figure 3). No changes to US LI-RADS were introduced
in 2018.

Ultrasound category
The study category, which is applied to the entire study as
opposed to individual observations, determines management
and potential need for further characterization of observations
with a contrast-based study.20 The three categories are; 1)
US-1: Negative, defined as no suspicious sonographic findings of HCC that warrant further evaluation. This includes the
absence of any focal lesions or the presence of only definitely
benign findings, such as focal fatty sparing, simple cyst,
or previously confirmed hemangioma. The recommended
management for category 1 is continued routine surveillance every 6 months.20,21 2) US-2: Subthreshold, defined
as the presence of one or more focal lesions, all <10 mm,
that are not definitely benign. The recommended management of US-2 involves close follow-up with short-interval
ultrasound every 3–6 months to identify growth beyond the
1 cm threshold, in which case, further characterization with
a contrast-based study is warranted.20,21 If an observation
in an US-2 study is stable in size for 2 years or greater, the
patient can return to routine 6-month surveillance. 3) US-3:
Positive, defined as the presence of one or more observations ≥10 mm and not definitely benign. Such observations
warrant further characterization with contrast-enhanced
imaging. Examples include solid nodules ≥10 mm of any
echogenicity (Figure 4), a new thrombus in a vein (whether
considered bland thrombus or TIV), or focal parenchymal
distortion ≥10 mm in size (Figure 5). The latter indicates
the possibility of diffuse or infiltrative subtype of HCC, and
it is defined by one or more of the following sonographic
findings: ill-defined area of heterogeneity, refractive edge
shadowing, loss of normal hepatic architecture, and distortion
of vessels. The management for US-3 is further characterized
with multiphase contrast-enhanced CT, MRI, or CEUS.20,21

Visualization score
The visualization score is assigned to each examination based
on technical quality and study limitations and conveys the
expected sensitivity of the examination for detection of liver
lesions. Multiple extrinsic and intrinsic factors can affect the
quality of ultrasound visualization of the liver parenchyma
including the patient body habitus, obscuration of the liver

Journal of Hepatocellular Carcinoma 2019:6
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US-1

Negative

US-2

Subthreshold

US-3

Positive

Category

Concept

Definition

US-1
Negative

No US evidence of HCC

No observation OR only definitely benign
observation(s)

US-2
Subthreshold

Observation(s) detected that may
warrant short-term US surveillance

Observation(s) <10 mm in diameter, not
definitely benign

US-3
Positive

Observation(s) detected that may
Observation(s) ≥10 mm in diameter, not
warrant contrast-enhanced imaging definitely benign OR new thrombus in vein

Figure 2 US LI-RADS US category.
Notes: Reproduced with permission from American College of Radiology. Ultrasound LI-RADS v2017. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/
LI-RADS/Ultrasound-LI-RADS-v2017.21
Abbreviations: ACR, American College of Radiology; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data System; US, ultrasound.

A

No or minimal limitations

B

Moderate limitations

C

Severe limitations

Score

Concept

Examples

A. No or
minimal
limitations

Limitations if any are
unlikely to meaningfully
affect sensitivity

Liver homogeneous or minimally heterogeneous
Minimal beam attenuation or shadowing
Liver visualized in near entirety

B. Moderate
limitations

Limitations may obscure
small masses

Liver moderately heterogeneous
Moderate beam attenuation or shadowing
Some portions of liver or diaphragm not visualized

C. Severe
limitations

Limitations significantly
lower sensitivity for focal
liver lesions

Liver severely heterogeneous
Severe beam attenuation or shadowing
Majority (>50%) of liver not visualized
Majority (>50%) of diaphragm not visualized

Figure 3 US LI-RADS visualization score.
Notes: Reproduced with permission from American College of Radiology. Ultrasound LI-RADS v2017. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/
LI-RADS/Ultrasound-LI-RADS-v2017.21
Abbreviations: ACR, American College of Radiology; LI-RADS, Liver Imaging Reporting and Data System.

by lung or bowel gas, a patient’s inability to hold their breath
or hold still, and hepatic parenchymal heterogeneity or sound
attenuation due to fibrosis/cirrhosis or steatosis.20 The three
scores are as follows: 1) Visualization A: No or minimal limitations, where the liver is visualized in its near entirety and
there is little or no compromise on the sensitivity of detection
of parenchymal masses. 2) Visualization B: Moderate limitations, which may decrease sensitivity of detection of small
masses. Examples include moderate hepatic heterogeneity or
difficult visualization of small portions of the liver. 3) Visualization C: Severe limitations, which may markedly lower the
sensitivity for detection of liver observations. These limitations include severe parenchymal heterogeneity, substantial

Journal of Hepatocellular Carcinoma 2019:6

beam attenuation, which results in nonvisualization of large
portions of the liver and diaphragm, or other factors that
limit visualization of >50% of the liver or diaphragm.20,21
It is important to note that currently the visualization score
does not impact management recommendations – this is
an active area of research, and as data and experience are
collected, future versions of US LI-RADS may incorporate
the visualization score into management recommendations.

LI-RADS diagnostic population
The criteria for the population on which LI-RADS can
be applied for diagnosis, as opposed to surveillance, was
introduced with v2017 and is carried over unchanged in
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transplantation candidates and patients posttransplant.15,22
The exclusion criteria include cirrhosis due to either vascular
disorders or cirrhosis due to congenital hepatic fibrosis.22–24
Vascular disorders leading to cirrhosis often have a large
number of arterialized benign nodules resembling HCC,
which can cause diagnostic confusion and reduce the diagnostic specificity. LI-RADS was not validated for use with
the pediatric population, and as such, patients under 18 years
old are excluded from the LI-RADS diagnostic population.15

CT/MRI LI-RADS
CT/MRI LI-RADS diagnostic categories

Figure 4 US LI-RADS Category 3 observation in a 59-year-old male with hepatitis
C cirrhosis undergoing US surveillance.
Notes: Sagittal US image shows a 3.6 cm solid hypoechoic observation with
lobulated margins in segment 6. This patient requires contrast-based studies; CEUS,
CECT, or CEMRI to further characterize the lesion.
Abbreviations: CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging
Reporting and Data System; US, ultrasound.

Although no new categories have been introduced in version
2018, the LR-5 category was modified to be congruent with
the AASLD practice guidelines. A brief review of the major
imaging features, ancillary imaging features, and categories
of LI-RADS is provided below, highlighting the modifications of the LR-5 category in version 2018.

Major imaging features used in CT/MRI
LI-RADS
Five major imaging features are used to assign LR-3 through
LR-5 categories for observations seen in patients at risk for HCC.
Their presence should be unequivocal to maintain high specificity for HCC.25 The goal of standardization of definitions of these
features is to encourage consistent application and interpretation,
ultimately resulting in more consistent patient care, clearer education, and more rigorous and reproducible research.25

Nonrim APHE

Figure 5 US LI-RADS Category 3 observation in a 70-year-old female with
cryptogenic cirrhosis undergoing US surveillance.
Notes: Transverse US image shows a large area of heterogeneity (arrows)
distinctive from background liver, shown to represent an HCC with infiltrative
appearance on a diagnostic CEUS (not shown).
Abbreviations: CEUS, contrast-enhanced ultrasound; HCC, hepatocellular
carcinoma; LI-RADS, Liver Imaging Reporting and Data System; US, ultrasound.

This feature is defined as nonrim enhancement of an observation in the arterial phase that is unequivocally greater
than the background liver tissue (Figure 6). It reflects the
process of angiogenesis, which is a key component of HCC
pathogenesis.26 This feature is considered present if either
the entire observation or only a portion is hyperenhancing.
The LR-5 category can only be assigned to observations
with unequivocal nonrim APHE (and not simply vascular
shunts with no correlation on other sequences; these are
considered LR-2 or -3 observations), which is consistent
with UNOS and OPTN criteria.27 Rim APHE is not a major
feature of HCC, but would instead prompt assigning the
LR-M category.27

Nonperipheral “washout”
v2018. The inclusion criteria includes patients with cirrhosis, patients with chronic hepatitis B viral infection, and
patients with current or prior HCC, including adult liver
54
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is a perceived temporal reduction in enhancement of an
observation relative to surrounding liver parenchyma from
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c orrelate with a pathologically identified true capsule.31,32 The
degree of enhancement typically increases from early to later
phases, reflecting the slow flow of intracapsular vessels. If
a “capsule” is nonenhancing or visible only on unenhanced
images, it is considered an ancillary feature “favoring HCC
in particular,” rather than a major LI-RADS feature.16 The
capsule appearance is not to be confused with “corona
enhancement” defined as periobservational enhancement in
the late arterial phase or early portal venous phase. Corona
enhancement is an ancillary feature favoring malignancy (but
not specific for HCC).15

Observation size
Figure 6 Seventy-one-year-old female demonstrating nonrim arterial phase
hyperenhancement.
Notes: Contrast-enhanced CT shows a large mass (arrows) in the left hepatic lobe,
partially exophytic, demonstrating heterogeneous arterial phase hyperenhancement.
Posthepatectomy pathology confirmed well-differentiated hepatocellular carcinoma.

an earlier to later phase.28 This feature may be applied to
any enhancing observation even in the absence of APHE.16
Although not fully understood, “washout” has been attributed
to the lower extracellular volume of a tumor compared with
background liver, which manifests as relative hypoenhancement in the postarterial extracellular phases. “Washout”
can be assessed in the portal venous or delayed phase if an
extracellular contrast agent is administered with MRI or CT.
When using gadoxetate disodium, “washout” can only be
assessed on the portal venous phase and cannot be reliably
evaluated on the transitional or hepatobiliary phases because
the background liver is changing as the hepatocytes take
up the contrast medium.29 One of the most reliable imaging hallmarks of HCC is the presence of nonrim APHE in
combination with nonperipheral washout appearance.30 As
opposed to nonperipheral “washout,” peripheral washout is
characteristic of intrahepatic cholangiocarcinoma (iCCA) and
other non-HCC malignancies, hence is used as a criterion for
assigning an LR-M category.15,27

Enhancing “Capsule”
“Capsule appearance” or “capsule” is defined as a uniform,
sharp, smooth rim of hyperenhancement around most or
all of an observation that is unequivocally thicker or more
conspicuous than fibrotic tissue surrounding cirrhosis-related
background liver nodules on portal venous, delayed, or
transitional phases. The term, capsule appearance or “capsule,” is preferred because its visualization does not always
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As the shape of observations may be ovoid or irregular, the
term size was adopted instead of diameter, which by definition, applies only to circles or spheres.27 Size is defined as
the largest outer-edge-to-outer-edge dimension of an observation, including the capsule if present.15 Accurate measurement
of observation size is important as it influences the staging of
HCC and plays a role in determining transplant eligibility.33
It is also used for the assessment of threshold growth during
follow-up imaging. The reader should measure observation
size on the phase or sequence in which the margins are
clearest. However, measurement during the arterial phase
or diffusion-weighted imaging should be avoided because
arterial phase measurement may overestimate size due to
differences in timing of the arterial phase between scans
or inadvertent inclusion of corona enhancement and the
diffusion-weighted images tend to have anatomic distortion,
which can affect measurements.16

Threshold growth
The definition of threshold growth was revised for v2018 to
be consistent with definitions endorsed by OPTN. It is now
defined as ≥50% increase in size of a mass in ≤6 months.16
An unequivocal increase in size that does not meet the definition of “threshold growth” is considered an ancillary feature
“favoring malignancy in general, not HCC in particular.”16
Caution is required when applying growth as a diagnostic
criterion for HCC, as other malignant neoplasms (eg, iCCA
and cHCC-CCA) can grow.25

Ancillary imaging features used in
CT/MRI LI-RADS
Unlike the major features, the incorporation of ancillary
imaging features, which are additional supportive features
favoring malignancy or benignity, into the final category
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assignment is considered optional.15 It is up to the radiologist’s clinical judgment to use these features to upgrade or
downgrade an observation to refine the final category.34
Ancillary features can be used to upgrade (only up to LR-4)
or downgrade an observation by one category only, regardless of how many ancillary features exist. However, ancillary
features cannot upgrade an observation from LR-4 to LR-5 as
these ancillary features do not currently have a high enough
specificity for diagnosing HCC.15,27 Ancillary features are
divided into three groups; 1) features favoring malignancy
in general, 2) features favoring HCC in particular, and 3)
features favoring benignity.15,34 If the features are conflicting,
ie, demonstrating a mix of features favoring both malignancy
and benignity, then the category should stay the same without change.27 Definitions of ancillary features are shown in
Figure 7 and have not changed from v2017. Of note, these
ancillary features apply to CT/MRI categorization and not
to CEUS as there are different distinct features related to
CEUS discussed later.

CT/MRI LI-RADS categories
CT/MRI LR-1 to LR-5
These represent the LI-RADS categories assigned to observations based on the probability of benignity vs malignancy
determined by the presence of major and ancillary imaging
features.15 LR-1 to LR-5 categories serve as a probabilistic

Ancillary features favoring malignancy
Favoring malignancy in general, not HCC in
particular
• US visibility as discrete nodule
• Subthreshold growth
• Restricted diffusion
• Mild–moderate T2 hyperintensity
• Corona enhancement
• Fat sparing in solid mass
• Iron sparing in solid mass
• Transitional phase hypointensity
• Hepatobiliary phase hypointensity

scale that reflects the probability of benignity, malignancy
in general, or HCC.

CT/MRI LR-NC
LR-NC is applied when there are considerable technical
limitations to the image quality and therefore, assigning an
LI-RADS category is not feasible. Based on the LI-RADS
management algorithm, the radiologist may recommend
repeat imaging at ≤3 months if the cause of the technical
limitation is resolvable or switch to an alternative imaging modality otherwise (eg, switching to CT from MRI if
blooming artifact from an embolization coil obscures much
of the liver).15,27

CT/MRI LR-TIV (definitely malignant with
TIV)
LR-TIV is assigned when definite tumor invasion of a vein
is observed regardless of whether there is an associated
parenchymal mass. Although TIV is usually due to HCC, it
can be caused by non-HCC malignancies such as iCCA and
combined HCC-CCA tumors.15,27

CT/MRI LR-M (malignancy not specific to
HCC)
This is assigned to probably or definitely malignant observations that do not meet the criteria for diagnosis of HCC.

Ancillary features favoring benignity
• Size stability > 2 years
• Size reduction
• Parallels blood pool
• Undistorted vessels
• Iron in mass, more than liver
• Marked T2 hyperintensity
• Hepatobiliary phase isointensity

Favoring HCC in particular
• Nonenhancing "capsule"
• Nodule-in-nodule
• Mosaic architecture
• Blood products in mass
• Fat in mass, more than adjacent liver
Figure 7 Ancillary imaging features used in LI-RADS CT/MRI.
Note: These ancillary features are supportive, and their use is optional. Reproduced with permission from American College of Radiology. Liver Imaging Reporting and Data
System version 2018 core. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS.16
Abbreviations: ACR, American College of Radiology; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data System; US, ultrasound.
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These lesions have a broad differential diagnosis that
includes not only HCC but also metastases, iCCA, or combined tumors.15,35 This category was devised to preserve the
specificity of the LR-5 category without loss of sensitivity
for detection of malignancy.

Assigning LI-RADS diagnostic
category using CT/MRI
Prior to applying the LI-RADS diagnostic algorithm, the
radiologist should ensure the patient is at increased risk of
developing HCC (as described above in LI-RADS diagnostic
population). Selectively applying LI-RADS algorithms to
at-risk populations is important in avoiding diagnostic errors
and maintaining the high specificity of the LR-5 category.5
LR-5 (definitely HCC) carries a nearly 100% specificity
for HCC, which eliminates the need for histopathological
confirmation. The diagnostic algorithm also should not be
applied to focal observations after locoregional therapy; the
treatment response algorithm should be applied instead.36
After these initial checks, a simplified four-step approach to
assigning LI-RADS categories can be performed, which is
unchanged in v2018.15

Step 1: Apply CT/MRI LI-RADS diagnostic
algorithm
First, the interpreting radiologist should examine the study
for quality and completeness in terms of necessary dynamic
enhancement phases to assess whether assigning a diagnostic
category is feasible.5,15,27 If key imaging phases are missing or obscured by artifact, then the observation should be
assigned LR-NC.
Once the quality and completeness of the study is confirmed, the liver should be evaluated for the presence of TIV
(Figure 8). If present, LR-TIV category should be assigned
regardless of the visualization of a parenchymal observation.
The reporting of LR-TIV should reflect the possible etiologies
of the venous invasion as follows: 1) if TIV is contiguous
with a targetoid parenchymal mass, report: “LR-TIV, may
be due to non-HCC malignancy”; 2) if TIV is contiguous
with an observation meeting LR-5 criteria, report: “LR-TIV,
definitely due to HCC”; and 3) in all other scenarios, report:
“LR-TIV, probably due to HCC.”5
After excluding the presence of TIV, the radiologist
should consider the features of individual observations and
determine if they are definitely (LR-1) or probably (LR-2)
benign.15 Definitely benign observations (LR-1) include hemangiomas, cysts, confluent fibrosis, and focal fat deposition
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or sparing. Probably benign observations (LR-2) have high
but not 100% probability of benignity, such as probable
hemangioma, probable perfusion alterations, and <20 mm
distinctive nodules with no major or ancillary features favoring malignancy.37,38
If an observation does not meet the criteria for LR-1 or
LR-2, then it should be determined if it meets the criteria
for LR-M (Figure 9). LR-M is assigned to solid observation
with a targetoid appearance (Figure 9) or with one or more
of the following imaging features: infiltrative appearance,
marked diffusion restriction, necrosis, or severe ischemia.5,35
If all the categories above are excluded after stepwise
consideration, the LI-RADS CT/MRI diagnostic table
(Figure 1) is applied and the observation is assigned a
category LR-3, LR-4, or LR-5 based on the presence of
major features.16 First, the observation should be assessed
for the presence of nonrim APHE. Second, the size of the
observation is measured to determine the correct column
in the table.5,16,27 Observations without APHE are separated
into <20 mm or ≥20 mm, while observations with nonrim
APHE are divided into <10 mm, 10–19 mm, and ≥20 mm.
Note that LR-5 category is reserved for observations,
which are both 10 mm or larger and demonstrate nonrim
APHE. Finally, the number of major features present
other than nonrim APHE is assessed to determine the
appropriate row in the table.5,16 The cell at the intersection
between the selected column and row contains the correct
LI-RADS category.

Step 2: Apply ancillary features
After assigning the initial LI-RADS category, the radiologist
may elect to apply ancillary features to adjust the category
as explained previously.5,34

Step 3: Apply tiebreaking rules
If, after following the algorithm through the first two steps,
there is still uncertainty between two categories (often due to
uncertainty regarding the presence of one or more imaging
features), the radiologist should then choose the category
associated with lower diagnostic certainty.16,27 For example,
if the radiologist is uncertain regarding the presence of TIV,
then LR-TIV should not be assigned.

Step 4: Perform a final check
Finally, the radiologist should consider whether the assigned
category seems appropriate based on their clinical judgment.
If it is appropriate, then the category is finalized, and the
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Figure 8 Fifty-eight-year-old man with cirrhosis (AFP=285 ng/mL) tumor in vein (TIV), probably due to hepatocellular carcinoma.
Notes: Gadobenate dimeglumine-enhanced MRI shows unequivocal enhancement of tissue (arrow) within the left portal vein, which meets the criterion for LR-TIV. Notice
that the tissue expands the lumen of the left portal vein, (A) hyperenhances in the arterial phase, (B) appears to washout in the portal venous phase and has high signal
intensity on (C) T2-weighted and (D) diffusion-weighted images. Involvement of the parenchyma by the tumor is more conspicuous on diffusion-weighted images (arrowhead in D).

radiologist should move on to the next observation. If not,
then the radiologist should reevaluate. Consultation with a
colleague for a second opinion may be reasonable if doubt
persists.5

CEUS LI-RADS
CEUS LI-RADS diagnostic categories
The diagnostic categories of CEUS (Figure 10) follow the
same general template of CT/MRI with some modifications
to the criteria required to assign these categories.39
58
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CEUS LR-NC
This category is usually assigned to observations where
significant limitations of the technique or poor quality of
the study due to external factors such as large body habitus
would prevent assigning an appropriate category to the
observation.39,40

CEUS LR-TIV
This is assigned when there is unequivocal visualization of
enhancing soft tissue in vein, regardless of visualization of
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Figure 9 Sixty-one-year-old man with chronic hepatitis C and cirrhosis.
Notes: A 2 cm observation in hepatic segment 5 shows (A) rim arterial phase hyperenhancement, (B) progressive delayed central enhancement on portal venous, and (C)
delayed phase, corresponding to a targetoid appearance (LR-M). Biopsy confirmed intrahepatic cholangiocarcinoma. Arrow shows the enhancement pattern.

CEUS LI-RADS® 2017 Categories
Diagnostic
categories
CEUS LR-NC

Probably or definitely malignant,
not necessarily HCC

Not categorizable
(due to image degradation
or omission)

CEUS LR-1

Definitely benign

CEUS LR-2

Probably benign

CEUS LR-3

Intermediate probability
of malignancy

CEUS LR-4

Probably HCC

CEUS LR-5

Definitely HCC

CEUS LR-M

CEUS LR-TIV

TIV

Figure 10 Diagnostic categories for CEUS LI-RADS.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data
System; LR-NC, LR-noncategorizable; TIV, tumor in vein.

parenchymal mass (Figure 11). CEUS is particularly helpful
in differentiation between TIV and bland thrombus depending on the time of microbubble contrast agent arrival to the
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vein, where early arrival (same as hepatic artery) favors TIV
and arrival several seconds after hepatic artery enhancement
would favor recanalized/nonocclusive bland thrombus.39
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Figure 11 CEUS LI-RADS TIV.
Notes: (A) Soft tissue in the portal vein (arrows) contiguous with a parenchymal mass (star) on B-mode ultrasound. (B, C) Both soft tissue within the portal vein (arrows)
and the mass (star) show arterial phase hyperenhancement and (D) mild washout in the late phase. CEUS LI-RADS TIV Criteria:
• Unequivocal arterial phase hyperenhancement and washout of soft tissue within the lumen of portal and/or hepatic veins.
• Must correspond on dual screen with mass in vein.
• Most LR-TIVs are HCC. Some are iCCA or cHCC-CCA.
• CEUS has been shown to have high sensitivity and specificity to diagnose TIV.
Abbreviations: CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; TIV, tumor in vein.

CEUS LR-M

CEUS LR-1 to LR-5

This category is assigned to a probably or definitely malignant
nodule, not particularly an HCC. The criteria for inclusion
into LR-M are shown in Figure 12.

These are the same categories as CT/MRI LI-RADS and are
assigned based on the probability of the observation being
benign (LR-1 and LR-2) or malignant (LR-3, LR-4, and
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• Distinct solid nodule with at least some enhancement in the arterial phase (regardless of
morphological pattern of degree) with either or both of the following:
• Early (<60s) washout relative to liver
• Marked washout resulting in a "punched out" appearance within 2 minutes of
contrast injection
OR
• Arterial phase rim enhancement, followed by washout (regardless of onset or degree)
• Multidisciplinary discussion for tailored work up is recommended. Often includes biopsy.
Figure 12 CEUS LI-RADS M criteria.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System.

LR-5). The major difference lies in the number of major and
ancillary features used to assign categories LR-3 to LR-5.39

Major imaging features used in
CEUS LI-RADS
Nonrim APHE
Similar to CT/MRI, nonrim APHE is one of the major features for CEUS LI-RADS and is considered present if demonstrated in either the entirety or just a portion of the nodule.
In contrast to CT/MRI, CEUS or grayscale ultrasound does
not visualize arterioportal shunts.40 Thus, in contradistinction to CT and MRI, most observations detectable by CEUS
are true nodules, and the presence of nonrim APHE by itself
prompts LR-4 categorization, regardless of nodule size. Of
note, if the APHE on CEUS is peripheral, discontinuous, and
globular, this is characteristic of a hemangioma.39

Washout
CEUS uses purely intravascular microbubble contrast agents,
which makes CEUS washout a true washout and does not
require using the terms washout appearance or “washout.”39
CEUS may be used to differentiate between typical HCC
and other malignant lesions that show APHE by assessment
of the onset (late vs early) and degree (mild vs marked) of
washout. Early-onset washout is considered present when
detected within 60 seconds of contrast agent injection, while
late-onset washout is characterized when detected at or after
the 60-second mark (Figure 13A).40 Marked washout is considered present when the nodule is mostly devoid of contrast
and is seen as “punched out” within 2 minutes after contrast
injection (Figure 13B). Marked washout is one of the characteristics of LR-M category. Mild washout, however, is defined
as a nodule demonstrating less degree of enhancement than
the surrounding liver parenchyma but still possessing some
degree of contrast enhancement.40 Nodules with mild washout
may later appear as showing marked washout. Thus, if this
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occurred after 2 minutes, it should still be categorized as
mild washout. HCCs usually show late-onset mild washout
in contrast to non-HCC malignancies that demonstrate earlyonset and/or marked washout (Figure 13C).39

Ancillary imaging features used in CEUS
LI-RADS
Ancillary features are applied less often in CEUS compared with CT/MRI. Similar to CT/MRI, they can be used
to upgrade or downgrade the category of an observation;
similarly, they cannot be used to upgrade LR-4 to LR-5.39
One advantage of CEUS over CT/MRI is the fewer number
of ancillary features, which reduces the interpretive burden
on the radiologist. Definitions of these features are shown
in Figure 14. They are also divided into three categories,
analogous to those used in CT and MRI.39

Assigning LI-RADS diagnostic category
using CEUS
CEUS is used similar to contrast-enhanced CT and MRI for
dynamic evaluation of lesions as well as surrounding blood
flow in the form of APHE and washout.39,40 Limitations of
CEUS are that it cannot be used for staging the entire liver,
and it has not been validated for the assessment of treatment
response.39,41 The population in which CEUS LI-RADS can
be applied is the same as that of CT/MRI. CEUS is indicated for the characterization of observations ≥10 mm when
detected on a surveillance ultrasound. It can also be used to
detect APHE when evaluation with CT or MRI is not possible
(or technically suboptimal). CEUS can be used to evaluate
previously biopsied observations with inconclusive histology and to differentiate between TIV and bland thrombus.39
Although the key concepts and principles of CEUS categories (Figure 10) appear similar to those of CT/MRI, there
are important differences that warrant separate diagnostic
features and characterization algorithms.39,40
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Figure 13 Washout.
Notes: (A) Early weak washout seen within 1 minute after contrast injection (CEUS LR-M feature). (B) Marked washout seen within 2 minutes after contrast injection (CEUS
LR-M feature). (C) Late and mild washout seen >1 minute after contrast injection (CEUS LR-5 feature).
Abbreviation: CEUS, contrast-enhanced ultrasound.

Ancillary features.
CEUS AFs favoring malignancy
Favoring malignancy in general, not HCC in
particular
• Definite growth
Favoring HCC in particular
• Nodule-in-nodule architecture
• Mosaic architecture

CEUS AFs favoring benignity
• Size stability ≥ 2 years
• Size reduction

If unsure about presence of any ancillary feature: characterize that feature as absent
Figure 14 AFs used in CEUS LI-RADS.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; AF, ancillary feature; CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging
Reporting and Data System.
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Step 1: Apply the CEUS LI-RADS
diagnostic algorithm
The steps to apply CEUS diagnostic algorithm (Figure 15)
follow closely those of CT/MRI. Below a few distinctions
are highlighted.
If a definitely benign lesion is eliminated from consideration, then an observation can be categorized as probably
benign (LR-2) based on the following criteria; 1) distinct
isoenhancing solid nodule <10 mm, 2) nonmass-like isoenhancing observation of any size while not being of typical
fatty change/sparing appearance, and 3) LR-3 nodules with
interval stability for at least 2 years. If an observation does not
meet the LR-1 or LR-2 criteria, then it should be evaluated for
the presence of LR-M criteria (Figure 12). On CEUS, these
criteria include 1) early washout relative to background liver
within 60 seconds of the contrast agent injection, 2) marked

washout resulting in a punched-out appearance within 2
minutes of contrast agent injection, and 3) rim APHE followed by washout.
After exclusion of LR-M, CEUS LI-RADS diagnostic
table should be applied and categories LR-3, LR-4, or LR-5
should be assigned to the observation based on size and the
presence of major features. LR-4 category is assigned to
observations that have high but not 100% probability of HCC.
LR-5 category is only assigned to observations at least 10 mm
or larger with nonrim APHE and mild late-onset washout. The
CEUS diagnostic table is similar to the CT/MRI diagnostic
table. One exception is that greater emphasis is placed on
nonrim APHE because any observation with nonrim APHE
is an arterialized nodule as described earlier. Another exception is that the characterization of washout is based on its
timing and degree, not just on its presence. Figures 15–17

Untreated observation visible on pre-contrast US and
without pathologic proof in patients at high risk for HCC
If cannot be categorized due to image degradation or omission

CEUS LR-NC

If TIV

CEUS LR-TIV

If definitely benign

CEUS LR-1

If probably but not definitely benign

CEUS LR-2

Probably or definitely malignant, not specific for HCC*

CEUS LR-M
* CEUS LR-M criteria:
● Rim APHE OR

Otherwise, use CEUS diagnostic table below

● Early (<60s) washout OR
● Marked washout

If intermendiate malignancy probablility

CEUS LR-3

If probably HCC

CEUS LR-4

If definitely HCC

CEUS LR-5

CEUS diagnostic table
APHE

No APHE

APHE **

<20

≥20

<10

≥10

No washout of any type

CEUS LR-3

CEUS LR-3

CEUS LR-3

CEUS LR-4

Late and mild washout

CEUS LR-3

CEUS LR-4

CEUS LR-4

CEUS LR-5

Nodule size (mm)

** APHE:

● Not rim (indicates LR-M)
● Not peripheral discontinuous globular (indicates hemangioma)

Figure 15 CEUS LI-RADS diagnostic algorithm and table.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; APHE, arterial phase hyperenhancement; CEUS, contrast-enhanced ultrasound; HCC, hepatocellular carcinoma; LIRADS, Liver Imaging Reporting and Data System; ; LR-NC, LR-noncategorizable; TIV, tumor in vein; US, ultrasound.
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Figure 16 CEUS LR-5.
Notes: (A) A 17 mm hypoechoic nodule on B-mode ultrasound. (B) The entire nodule shows hyperenhancement in the arterial phase. (C) At 1 minute, the nodule is
isoenhancing compared with the surrounding liver parenchyma. (D) The nodule shows mild but definite hypoenhancement compared with the surrounding liver parenchyma
at 2 minutes. This is late and mild washout. Arrows show the outline of the nodule.
Abbreviation: CEUS, contrast-enhanced ultrasound.

64

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Journal of Hepatocellular Carcinoma 2019:6

Dovepress

Elsayes et al

Journal of Hepatocellular Carcinoma downloaded from https://www.dovepress.com/ by 128.163.8.74 on 04-Oct-2019
For personal use only.

A

B

B mode

C

11 s

D

2m

5.5 m

Figure 17 CEUS LR-4.
Notes: (A) A 12 mm hypoechoic nodule on B-mode ultrasound. (B) The entire nodule shows hyperenhancement in the arterial phase. (C) At 2 minutes, the nodule is
isoenhancing compared with the surrounding liver parenchyma. (D) The nodule remains isoenhancing at 5.5 minutes without washout. Arrows show to the outline of the
nodule.
Abbreviation: CEUS, contrast-enhanced ultrasound.
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show examples of different nodules with CEUS categories
assigned to them.
Steps 2 (apply ancillary features) (Figure 18), 3 (apply
tiebreaking rules) (Figure 19), and 4 (final check) are conceptually identical to their CT/MRI counterparts.39

LI-RADS treatment response
LI-RADS treatment response categories
The LI-RADS treatment response algorithm was introduced
in v2017 to guide interpretation of response following
locoregional therapy and to improve clarity and consistency
of communication between multidisciplinary teams managing HCC patients.27
Response evaluation criteria in solid tumors and modified response evaluation criteria in solid tumor serve as the
standard criteria for assessing treatment response in o ncology

clinical trials; however, these systems are not designed for
use in routine practice and do not currently contribute to
OPTN staging for organ allocation in liver transplantation.
The LI-RADS treatment response algorithm and categories
apply to observations treated by a range of locoregional
therapies, but do not apply to systemic treatment response;
the system can be used with caution in patients undergoing
both locoregional and systemic therapy when the locoregional
treatment effects are dominant.36 The treatment response
algorithm defines specific imaging features/criteria for
individual response categories, which are intended to communicate the probability of residual viable tumor following
therapy. It is worth mentioning that these criteria primarily
reflect vascularization of tissues as a surrogate for viability;
this does not necessarily translate to complete pathological
response due to the inability of imaging to detect microscopic

≥ 1 AF favoring malignancy: upgrade by 1 category up to LR-4
(absence of these AFs should not be used to downgrade)

CEUS LR-1

Probably HCC
CEUS LR-3

CEUS LR-2

CEUS LR-4

CEUS LR-5

≥ 1 AF favoring benignity: downgrade by 1 category
Figure 18 CEUS LI-RADS AFs upgrade and downgrade of categories.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; AF, ancillary feature; CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System.

If unsure about presence of TIV, do not categorize as CEUS LR-TIV

No TIV

CEUS
LR-TIV

If unsure between two categories, choose the one reflecting lower certainty
Lower certainly of
benignity

CEUS
LR-1

CEUS
LR-2

Lower certainly of
malignancy

CEUS
LR-3

CEUS
LR-4

CEUS
LR-5

Lower certainly of
hepatocellular
origin

CEUS LR-M
Figure 19 CEUS LI-RADS tiebreaking rules.
Notes: Reproduced with permission from American College of Radiology. CEUS LI-RADS v2017. Available from: https://www.acr.org/Clinical-Resources/Reporting-andData-Systems/LI-RADS/CEUS-LI-RADS-v2017.39
Abbreviations: ACR, American College of Radiology; CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System; TIV, tumor in vein.

66

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Journal of Hepatocellular Carcinoma 2019:6

Elsayes et al

foci of residual tumor.36,42 The categories and their definitions
are listed below and provided in Figure 20.

patterns in the absence of technical or patient-related
limitations.27

LR-TR nonevaluable

Assigning LI-RADS treatment response
categories using CT/MRI

This category is assigned when the treatment response
cannot be evaluated due to poor image quality, inadequate
technique, or time interval after therapy too soon for reliable
interpretation.36

LR-TR nonviable
The nonviable category should be assigned to treated lesions
with no appreciable enhancement or to lesions demonstrating
expected posttreatment enhancement patterns.16 For example,
a common expected posttreatment enhancement pattern
is thin rim enhancement that becomes progressively more
intense on postarterial phases.

LR-TR viable
The viable category should be assigned to treated lesions with
nodular, mass-like, or thick irregular regions of APHE, washout appearance, or enhancement similar to pretreatment.36

LR-TR equivocal
This category is applied to lesions that cannot be clearly categorized as viable or nonviable due to atypical enhancement

Treated
observation

Similar to the diagnostic systems, the treatment response
assessment is done in four steps.27

Step 1: Apply LI-RADS CT/MRI treatment
response algorithm
First, the reader should confirm that the imaging study is
adequate, ie, without significant degradation or omission
of required images. If the required images are not present,
then category LR-TR nonevaluable should be assigned.36 If
treatment response can be evaluated, then one of the three
LR-TR categories should be assigned.

Step 2: Measure observation size
LR-TR viable and LR-TR equivocal lesions should be measured. The region of viable or potentially viable tumor is
measured as the longest dimension of the enhancing tissue,
without traversing the nonenhancing area. This one-dimensional measurement serves as the observation size when
reporting LR-TR viable or LR-TR equivocal lesions.27 When

If unable to evaluate
treatment response

If able to evaluate
treatment response,
assign one category

LR-TR nonevaluable

LR-TR nonviable

LR-TR equivocal

LR-TR viable

4 months post MWA

5 months post Y90

10 months post Y90

Portal venous

Arterial
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Figure 20 Treatment response categories with examples from a 70-year-old man who underwent transarterial radioembolization (Y90) followed by transarterial bland
embolization and microwave ablation (MWA).
Notes: Left column shows no evidence of enhancement after MWA, categorized as LR-TR nonviable. Center column shows ill-defined enhancement (arrows) 5 months
after Y90, categorized as LR-TR equivocal. Right column shows mass-like arterial phase hyperenhancement in the treated lesion (arrowheads), categorized as LR-TR viable.
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present, the size of residual viable tumor helps dictate management decisions and track tumor burden, eg, while awaiting
transplantation. If there is no lesional enhancement or the
enhancement pattern is expected for the applied therapy, then
the appropriate treatment category is LR-TR nonviable; in
this context, the size of viable tumor has no meaning and a
size measurement does not need to be reported.15

Steps 3 and 4: Apply tiebreaking rule and
perform final check
If the radiologist is undecided on the posttreatment category,
LR-TR equivocal should be chosen to reflect the lower
certainty of residual tumor. As a final check, the radiologist
should question the assigned category and reevaluate if that
category is inappropriate.15 CT/MRI diagnostic categories
should still be used for untreated lesions or new lesions
developing elsewhere in the liver.

Conclusion
LI-RADS has been created as a dynamic system with regular
updates to maintain best practices based on latest evidence
and expert multidisciplinary consensus. LI-RADS has been
refined and expanded over multiple updates to now also
address ultrasound-based surveillance, CEUS for HCC
diagnosis, and CT/MRI for assessing treatment response after
locoregional therapy in addition to CT/MRI diagnosis. LIRADS is consistent with the National Comprehensive Cancer
Network (NCCN) guidelines and can be easily converted to
OPTN classes for liver transplant evaluation. The new version of LI-RADS is now fully integrated into the AASLD
2018 HCC clinical practice guidance, which represents a
major step toward widespread endorsement of LI-RADS in
clinical practice.
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